PAK2 and head and neck squamous cell carcinoma: Although the current GDSC dataset is limited, we were able to validate the PAK2 serine–threonine kinase as a druggable dependency that is not well studied in HNSCC and to identify two potential genetic biomarkers of PAK2 inhibitor response.